ALLMedicine™ Apolipoprotein A-I Center
Research & Reviews 626 results
https://doi.org/10.1097/j.pain.0000000000002834
Pain Navia-Pelaez JM, Paes Lemes JB et. al.
Feb 1st, 2023 - Nociceptive afferent signaling evoked by inflammation and nerve injury is mediated by the opening of ligand- and voltage-gated receptors/channels localized to cholesterol-rich lipid raft membrane domains. Dorsal root ganglia (DRG) nociceptors expr...
https://clinicaltrials.gov/ct2/show/NCT04216342
Jan 31st, 2023 - Cardiovascular disease (CVD) is one of the leading causes of death worldwide and elevated levels of cholesterol and triglycerides on plasma lipoproteins are major contributing risk factors. Therapeutic agents that increase High Density Lipoprotein...
https://clinicaltrials.gov/ct2/show/NCT02315586
Jan 20th, 2023 - Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive disease that occurs primarily in older individuals, 55 to 75 years of age, with a median survival of approximately 3 years from time of diagnosis. At present, there are no effective trea...
https://doi.org/10.1073/pnas.2209528120
Proceedings of the National Academy of Sciences of the Un... Liao YE, Xu Y et. al.
Jan 18th, 2023 - Sepsis is a lethal syndrome manifested by an unregulated, overwhelming inflammation from the host in response to infection. Here, we exploit the use of a synthetic heparan sulfate octadecasaccharide (18-mer) to protect against sepsis. The 18-mer n...
https://doi.org/10.1016/j.jpain.2023.01.001
The Journal of Pain; Cisneros E, Martínez-Padilla A et. al.
Jan 14th, 2023 - Chronic visceral pain (CVP) is extremely difficult to diagnose, and available analgesic treatment options are quite limited. Identifying the proteins secreted from the colonic nociceptors, or their neighbor cells within the tube walls, in the cont...
Clinicaltrials.gov 22 results
https://clinicaltrials.gov/ct2/show/NCT04216342
Jan 31st, 2023 - Cardiovascular disease (CVD) is one of the leading causes of death worldwide and elevated levels of cholesterol and triglycerides on plasma lipoproteins are major contributing risk factors. Therapeutic agents that increase High Density Lipoprotein...
https://clinicaltrials.gov/ct2/show/NCT02315586
Jan 20th, 2023 - Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive disease that occurs primarily in older individuals, 55 to 75 years of age, with a median survival of approximately 3 years from time of diagnosis. At present, there are no effective trea...
https://clinicaltrials.gov/ct2/show/NCT00768274
Nov 4th, 2022 - One-third of the US population, almost 80 million adults, have cardiovascular disease and mortality associated with heart disease which still remains a leading cause of death around the world. The major risk factors for cardiovascular disease asso...
https://clinicaltrials.gov/ct2/show/NCT03641742
Jul 21st, 2022 - The NHLBI has prioritized research focused on the primary prevention of chronic lung diseases, including ILD. The overall goal of this study is to conduct studies preparatory to and requisite for the testing of ILD preventative interventions. In t...
https://clinicaltrials.gov/ct2/show/NCT05210023
Jan 27th, 2022 - After the selection of the population, the patients undergo a molecular diagnosis: DNA will be extracted from peripheral blood with the High Pure PCR (Polymerase Chain Reaction) Template Preparation Kit (Roche). Then certain polymorphisms will be ...
News 14 results
https://www.medpagetoday.com/cardiology/atherosclerosis/74221
Jul 25th, 2018 - Action Points Two studies of recombinant apolipoprotein A-I (the major HDL apolipoprotein) products failed to show an effect on coronary plaque volume assessed by intravascular ultrasound (IVUS). Note that based on these studies, the development o...
https://www.medpagetoday.com/cardiology/prevention/69812
Dec 11th, 2017 - Based on the COMPASS trial results, the ultra-low 2.5-mg twice-daily dose of rivaroxaban (Xarelto) has been submitted for a supplemental indication in prevention of major cardiovascular events in coronary artery disease or peripheral artery diseas...
https://www.medscape.com/viewarticle/877757
Mar 27th, 2017 - WASHINGTON, DC — Infusing an engineered HDL-cholesterol mimetic into patients who recently have had acute coronary syndrome (ACS) did not reduce the volume of plaque in arteries as measured by intravascular ultrasound (IVUS) compared with placebo,...
https://www.medpagetoday.com/rheumatology/arthritis/62498
Jan 12th, 2017 - Action Points Baricitinib, an investigational reversible inhibitor of tyrosine kinases JAK 1 and JAK2 signaling, increases the level of serum lipids, including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-...
https://www.mdedge.com/chestphysician/article/119301/lipid-disorders/video-milano-pilot-marks-end-road-hdl-mimetic
Susan London, MDedge News
Dec 2nd, 2016 - NEW ORLEANS – The future doesn’t look bright at the moment for use of agents that mimic HDL cholesterol to reverse coronary disease, based on disappointing results of the randomized, phase II MILANO-PILOT trial. Among 120 patients with recent acut.